HC Wainwright Reiterates Buy Rating for Aprea Therapeutics (NASDAQ:APRE)

Aprea Therapeutics (NASDAQ:APRE)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $20.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 434.76% from the stock’s previous close.

Aprea Therapeutics Trading Up 1.9 %

Shares of APRE stock opened at $3.74 on Wednesday. Aprea Therapeutics has a 12 month low of $2.15 and a 12 month high of $8.85. The company has a market capitalization of $20.31 million, a P/E ratio of -1.33 and a beta of 0.75. The stock has a 50 day moving average of $3.35 and a two-hundred day moving average of $3.46.

Aprea Therapeutics (NASDAQ:APRE) last issued its earnings results on Thursday, November 7th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.11. The firm had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $0.45 million. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. Sell-side analysts predict that Aprea Therapeutics will post -2.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aprea Therapeutics stock. Dimensional Fund Advisors LP bought a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned approximately 0.20% of Aprea Therapeutics at the end of the most recent quarter. 34.19% of the stock is owned by institutional investors.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.